Results 221 to 230 of about 649,195 (266)

Jianpi Qingre Tongluo prescription (Huangqin Qingre Chubi capsule) protects the self-perception of patients with gouty arthritis through neutrophil to lymphocyte ratio: A nested case-control study. [PDF]

Medicine (Baltimore)
Chen Y, Fang Y, Qi Y, Liu J.
europepmc   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Effects of auricular therapy on pain and anxiety in patients undergoing hysteroscopic examination: A retrospective comparative study. [PDF]

Medicine (Baltimore)
Zhu W, Zhou A, Jin X.
europepmc   +1 more source

SAS/ETS user's Guide

, 1984
SAS Institute
core  

Effect of esomeprazole on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader, in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study is to evaluate the effects of multiple doses of esomeprazole, a strong proton pump inhibitor and acid‐reducing agent, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera oestrogen receptor degrader.
Lana Tran, Naihan Chen, Jennifer A. Winton, Kyle T. Matschke, Smita P. Goodman, Kimberly C. Lee, Yuanyuan Zhang, Weiwei Tan   +7 more
wiley   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Intervention effects of different brands of botulinum toxin type A on Meige syndrome with anxiety symptoms. [PDF]

Front Neurol
Tang Y, Liu R.
europepmc   +1 more source

SAS 9.4 SQL procedure: user's guide

, 2015
SAS Institute
core  

Long non-coding RNA (lncRNA) <i>CDKN2A-DT</i> promotes proliferation, migration, and invasion of oral squamous cell carcinoma via the PI3K/AKT/mTOR axis. [PDF]

Transl Cancer Res
Liao K, Lv W, Feng B, Su X, Huang X.
europepmc   +1 more source

Getting Started with SAS Enterprise Miner 14.1

, 2015
SAS Institute
core